Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure. It is known to act as a serotonin 5-HT<sub>2A</sub> receptor partial agonist. The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT<sub>2A</sub> receptor antagonist ketanserin. Catharanthalog is said to have relatively low bloodâÂÂbrain barrier permeability owing to relatively low lipophilicity. It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug was first described in the scientific literature by 2025.